Ixempra - 2007 FDA approvals

Drug: Ixempra (ixabepilone)
Indication: Cancer
Company: Bristol-Myers Squibb
Approval Date: October 16, 2007

Scoop: Ixempra gained FDA approval as a stand-alone treatment for patients who've failed other chemotherapy and for use with Roche's Xeloda in patients whose cancer has spread. Ixempra is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones. A treatment course of Ixempra is expected to cost $18,000 to $23,000, and is expected to earn BMS $500 million in annual sales by 2010.

More News:
BMS cancer med could earn $500M. Report

Ixempra - 2007 FDA approvals

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.